Many patients begin noticing changes within the first few weeks as GLP-1 medications help reduce appetite and calorie intake
Initial concerns were raised after findings from the cardiovascular outcome trial (CVOT), Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes 6 (SUSTAIN 6), revealed a greater risk of DR-related complications, defined as the need for laser therapy, intravitreal injections, development of vitreous hemorrhage, and blindness, in semaglutide users compared to placebo (3.0% vs 1.8%, HR=1.76, P =.02)
Separately, FDA lists GHK-Cu for injectable routes under safety concerns, citing immunogenicity risk and limited human safety data [8]
Related oral-semaglutide reading: Rybelsus Coupon, Rybelsus Generic, Rybelsus Weight Loss, Rybelsus For Type 2 Diabetes